Lung Cancer | Specialty

Monoclonal Antibodies in Squamous Cell Lung Cancer

March 3rd 2016

Treatment Options for Relapsed Squamous NSCLC

March 3rd 2016

Maintenance Therapy in Squamous NSCLC

March 3rd 2016

Nab-Paclitaxel plus Carboplatin in Squamous NSCLC

March 3rd 2016

Optimal Chemotherapy for Squamous NSCLC

March 3rd 2016

Mutation Testing and Lung-MAP Clinical Trial

March 3rd 2016

Mutational Landscape of Squamous NSCLC

March 3rd 2016

Clinical Presentation of Squamous NSCLC

March 3rd 2016

Tremelimumab Misses OS Endpoint in Phase IIb Mesothelioma Trial

March 1st 2016

Second- or third-line treatment with tremelimumab monotherapy failed to improve overall survival compared with placebo for patients with unresectable malignant mesothelioma.

Peregrine Stops Phase III Trial of Bavituximab in NSCLC

February 26th 2016

The phase III SUNRISE trial comparing bavituximab plus docetaxel with docetaxel and placebo for patients with non–small cell lung cancer has been halted following a futility analysis.

Expert Discusses Translating EGFR Mutation Status Into Action in NSCLC

February 24th 2016

Mark Socinski, MD, discusses the three generations of drugs are now available to treat patients with EGFR-mutant non–small cell lung cancer, and mutation testing for patients diagnosed with advanced or metastatic disease has been incorporated into clinical practice guidelines.

Dr. Filosso on Future of Treating Patients With Lung NETs

February 16th 2016

Pier Luigi Filosso, MD, associate professor of Thoracic Surgery, University of Torino, Italy, discusses future approaches to treating patients with neuroendocrine tumors of lung origin.

Immunotherapy Continues Rapid Advance in NSCLC

February 16th 2016

Naiyer Rizvi, MD, discusses the role of PD-L1 testing, which PD-1/PD-L1 agents have the most potential, and what is on the horizon for the use of immunotherapies in non-small cell lung cancer.

Dr. Martins on Patient Selection for Nivolumab in NSCLC

February 15th 2016

Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).

Combining Therapies with Antiangiogenic Antibodies

February 15th 2016

Ramucirumab for Squamous or Nonsquamous Lung Cancer

February 15th 2016

Use of Bevacizumab for Lung Cancer

February 15th 2016

Therapeutic Targeting Against Abnormal Tumor Vasculature

February 15th 2016

Dysregulated Angiogenesis in Cancer

February 15th 2016

PD-L1/CTLA-4 Dual Blockade Shows Promise in NSCLC

February 12th 2016

A combination checkpoint blockade with the PD-L1 inhibitor durvalumab and the anti–CTLA-4 agent tremelimumab induced a response rate of 23% in patients with advanced non–small cell lung cancer.